Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

Novartis announced that it has agreed to terms to acquire Anthos Therapeutics for an upfront payment of $925 million. The deal will include abelacimab, a Factor XI-inhibiting monoclonal antibody in ...

Novartis announced a definitive agreement to acquire private biotech Anthos Therapeutics, which will strengthen its cardiovascular pipeline by adding abelacimab, the latter’s lead pipeline ...

(Il Sole 24 Ore Radiocor) - Milano, 11 feb - Blackstone Life Sciences and Anthos Therapeutics said they have entered into an agreement with Swiss pharmaceutical company Novartis for it to buy the ...

Novartis announced a definitive agreement to acquire private biotech Anthos Therapeutics, which will strengthen its cardiovascular pipeline by adding abelacimab, the latter’s lead pipeline candidate ...

Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for approximately $3.1bn. The deal gives Novartis access to abelacimab, which ...

Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B.

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...